Publication | Open Access
Hypertension and Diabetes Delay the Viral Clearance in COVID-19 Patients
121
Citations
22
References
2020
Year
Unknown Venue
HypertensionHeart FailureDisease ProgressionCovid-19 EpidemiologyLogistic AnalysisCovid-19Viral PersistenceClinical EpidemiologyClinical DiseasePublic HealthAbstract Objectives ComorbiditiesViral ClearanceDiabetes ManagementLong CovidCardiovascular EpidemiologyDisease Risk AssessmentCovid-19 PandemicRiskVirologyChronic Viral InfectionEpidemiologyCardiovascular DiseaseGlobal HealthDiabetesWorse PrognosisMedicine
Abstract Objectives Comorbidities have significant indications for the disease outcome of COVID-19, however which underlying diseases that contribute the most to aggravate the conditions of COVID-19 patients is still largely unknown. SARS-CoV-2 viral clearance is a golden standard for defining the recovery of COVID-19 infections. To dissect the underlying diseases that could impact on viral clearance, we enrolled 106 COVID-19 patients who were hospitalized in the Zhongnan Hospital of Wuhan University, Wuhan, China between Jan 5 and Feb 25, 2020. Methodology We comprehensively analyzed demographic, clinical and laboratory data, as well as patient treatment records. Survival analyses with Kaplan-Meier and Cox regression modelling were employed to identify factors influencing the viral clearance negatively. Results We found that increasing age, male gender, and angiotensin-converting enzyme 2 (ACE2) associated factors (including hypertension, diabetes, and cardiovascular diseases) adversely affected the viral clearance. Furthermore, analysis by a random forest survival model pointed out hypertension, cortisone treatment, gender, and age as the four most important variables. Conclusions We conclude that patients at old age, males, and/or having diseases associated with high expression of ACE2 will have worse prognosis during a COVID-19 infections.
| Year | Citations | |
|---|---|---|
Page 1
Page 1